Greenwich LifeSciences Inc. Common Stock (GLSI)

FairStock Score: 10/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-and-Graham style investor, I start with whether this is a business I can value. Greenwich LifeSciences is a clinical-stage biopharmaceutical company with no reported revenue and a lead candidate, GP2, in a Phase III trial for HER2/neu breast cancer recurrence, plus FLAMINGO-01 studies of GLSI-100. That is an option on science, not a proven business. The filed figures show losses every year: fiscal 2023 net loss $8.9M and EPS -$0.69; fiscal 2024 net loss $17.4M and EPS -$1.34; fiscal 2025 net loss $19.4M and EPS -$1.43. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $3.9M and EPS -$0.27; in fiscal Q1 2026, ended 2026-03-31, net loss was $5.7M and EPS -$0.39. Losses have widened, not narrowed. Trailing free cash flow is -$12.5M, a FairStock-calculated FCF yield of -5.5%. At the close on 2026-10-13, FairStock's P/E was -10.13 and P/B 73.81; ROE was -986.32% and ROCE -235.98%, and its Piotroski F-Score was 0/9. The Altman Z-Score is 8.86, but without revenue or profits I treat that as secondary. A durable moat is unproven; value depends on trial outcomes, regulatory approval, reimbursement, and financing. The $227.5M market cap and $15.50 price already reflect substantial hope. Graham would ask for a margin of safety; here the numbers offer little, and the Lynch category is none because the company lost money in each of the last four years.

In plain English: Greenwich LifeSciences is a small drug company that is still testing its main product for a type of breast cancer. It has no product sales yet and has lost money in recent years, so the business looks weak on its reported numbers. At the recent price of $15.50, the stock looks expensive compared with those numbers and mainly reflects hope that its tests will succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-K (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer